Advertisement

Antiandrogene in der Therapie des fortgeschrittenen Prostatakarzinoms

  • U. W. Tunn

Zusammenfassung

Antiandrogene sind als Substanzen definiert, die die Wirkung von Androgenen am Erfolgsorgan neutralisieren. Prinzipiell sind 2 Typen von Antiandrogenen zu differenzieren:
  • das steroidale Antiandrogen vom Cyproteronacetat-Typ und das nichtsteroidale Antiandrogen vom Flutamid-Typ.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Arnhold J, Bingold M, Tunn UW (1986) Transrectale Prostatasonographie — ein prognostisches Kriterium beim Prostatakarzinom? Verh Dtsch Ges Urol, 37. Tagung, Mainz. Thieme, Stuttgart New York, S 529Google Scholar
  2. 2.
    Bingold M, Arnhold J, Tunn UW (1987) Cytostase als primäre oder sekundäre Therapie des fortgeschrittenen Prostatakarzinoms? Verh Dtsch Ges Urol, 38. Tagung, Würzburg, im DruckGoogle Scholar
  3. 3.
    Bracci U (1979) Antiandrogens in the treatment of prostatic cancer. Eur Urol 5: 303–306PubMedGoogle Scholar
  4. 4.
    Geller J, Vazakas G, Fruchtman B, Newman H, Nakao K, Loh A (1986) The effect of cyproterone acetate on advanced carcinoma of the prostate. Surg Gynecol Obstet 127 /4: 748–758Google Scholar
  5. 5.
    Giulani L, Pescatore D, Gilberti C, Martorana G, Natta G (1980) Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy-5-year-follow-up. Eur Urol 6: 145–148Google Scholar
  6. 6.
    Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–17PubMedCrossRefGoogle Scholar
  7. 7.
    Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (1980) Treatment of advanced prostatic cancer with parenteral cyproterone acetate: A phase III randomised trial. Brit J Urol 52: 208Google Scholar
  8. 8.
    Jacobi GH, Tunn UW, Senge TH (1982) Clinical experience with cyproterone acetate for palliation of inoperable prostate cancer. In: Jacobi GH, Hohenfellner R (EDS) Prostate Cancer. Williams & Wilkins, Baltimore London, PP 305–319Google Scholar
  9. 9.
    Jacobi GH (1983) Intramuscular cyproterone acetate treatment for advanced prostatic carcinoma: results of the first multicentric randomized trial. In: Schröder FH (ed) Androgens and Antiandrogens, International Symposium June 5th, 1982. Schering Nederland BVGoogle Scholar
  10. 10.
    Karr JP, Murphy GP (1983) Treatment of prostatic carcinoma with combinations of drugs and hormones. In: Bruchovsky N, Chapdelaine A, Neumann F, Brückner R (eds) Regulation of Androgen Action. Berlin, S 81–86Google Scholar
  11. 11.
    Klosterhalfen H, Becker H (1983) Antiandrogentherapie des Prostatakarzinoms — Klinische Erfahrungen mit Androcur/Androcur-Depot. In: Klosterhalfen H (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms. Vortragsveranstaltung für Urologen, Berlin 1982/83. Med Wiss Buchreihe, Schering AG, Berlin, S 63–65Google Scholar
  12. 12.
    Labrie F, Dupont A, Belanger A, Lacoursiere, Raynaud JP, Husson JM, Gareau J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4: 579–594PubMedCrossRefGoogle Scholar
  13. 13.
    Murphy GP, Huben RP, Priore R (1986) Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metatastatic prostate cancer. Urology XXVIII: 36–40Google Scholar
  14. 14.
    Nagel R, Leistenschneider W (1983) Chemotherapie des Prostatakarzinoms. In: Klosterhalfen H (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms, Med Wiss Buchreihe, Schering AG, 55–62Google Scholar
  15. 15.
    Page JP, Levi JA, Woods RL, Tattersall MN, Fox RM, Coates AS (1985) Randomized trial of combination chemotherapy in hormone resistant metastatic prostate carcinoma. Cancer Treat Rep 69 /1: 105–107PubMedGoogle Scholar
  16. 16.
    Pavone-Macaluso M and EORTC-GU-Group (1982) Medroxyprogesterone acetate, diethylstil-boestrol and cyproterone acetate in the treatment of prostatic cancer. Interim report of a prospective study of the European Orgazination for Research on the Treatment of Cancer (EORTC). Genitourinary Tract Cooperative Group — Excerpt Medicae Int Congr Ser 611: 436–444Google Scholar
  17. 17.
    Pescatore D, Giberti C, Mortorana G, Natta G, Giuliani L (1980) The effect of cyproterone acetate and orchiectomy on metastases from prostatic cancer. Eur Urol 6: 149–153PubMedGoogle Scholar
  18. 18.
    Sander S, Nissen-Meyer R, Aakvaag A (1982) Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study. Scand J Urol Nephrol 16: 193Google Scholar
  19. 19.
    Schmidt JD, Scott WW, Gibbons R, Johnson DE, Prout GR, Loening S, Soloway M, De Kernion H, Pontes JE, Slack NH, Murphy GP (1980) Chemotherapy programs of the National Prostatic Cancer Projekt ( NPCP ). Cancer 45: 1937–1946Google Scholar
  20. 20.
    Scott WW, Schirmer HK (1966) A new oral progestional steroid effective in treating prostatic cancer. Trans Am Assoc Genitourin Surg 58: 54–60PubMedGoogle Scholar
  21. 21.
    Servadio C, Mukamel E, Lurie H, Nissenkorn I (1983) Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. Urology XXI /5: 492–495Google Scholar
  22. 22.
    Sogani PC, Vagaiwala MR & Whitmore WF (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54: 744–750PubMedCrossRefGoogle Scholar
  23. 23.
    Tunn UW, Senge Th, Jacobi GH (1983a) Klinische Erfahrungen mit Cyproteronacetat als Monotherapie beim inoperablen Prostatakarzinom. In: Klosterhalfen H (Hrsg) Therapie des fortgeschrittenen Prostatakarzinoms. Vortragsveranstaltung für Urologen, Berlin 1982/83. Med Wiss Buchreihe, Schering AG, Berlin, S 67–76Google Scholar
  24. 24.
    Tunn UW, Graff J, Senge Th ( 1983 b) Treatment of inoperable prostatic cancer with cyproterone acetate. In: Schröder FH (ed) Androgens and anti-androgens. Schering Nederland BV, S 149–159Google Scholar
  25. 25.
    De Voogt HH, EORTC-GU-Group (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on the Treatment of Cancer trials 30761 and 30762. J Urol 135: 303–307Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • U. W. Tunn

There are no affiliations available

Personalised recommendations